Download Dual antiplatelet therapy for coronary and peripheral arterial disease Ebook PDF

Dual Antiplatelet Therapy for Coronary and Peripheral Arterial Disease

Dual Antiplatelet Therapy for Coronary and Peripheral Arterial Disease
A Book

by Sorin Brener

  • Publisher : Academic Press
  • Release : 2021-01-09
  • Pages : 220
  • ISBN : 0128205377
  • Language : En, Es, Fr & De
GET BOOK

Dual Antiplatelet Therapy for Coronary and Peripheral Arterial Disease is a complete reference containing updated information on the advantages and disadvantages of dual antiplatelet therapy, its duration, composition and anticipated changes. The basis for DAPT in arterial disease is discussed, allowing readers to understand platelet physiology and its relevance to ischemic events. Data on shorter than usual duration of DAPT, and on extended therapy beyond the recommendation of current guidelines is presented in great detail, summarizing a large body of evidence into concrete, relevant recommendation that is readily adaptable by practicing clinicians. A clinically relevant and updated compendium of data pertaining to this field is also presented, as well as the anticipated trends and innovations likely to occur in the next 3-5 years. Summarizes a large body of evidence into concrete, relevant recommendations that is readily adapted by practicing clinicians Explores the current status of DAPT, controversial topics, and future developments and trends in this field Edited and contributed by renowned cardiologists in the field

Testing of Cyp2c19 Variants and Platelet Reactivity for Guiding Antiplatelet Treatment

Testing of Cyp2c19 Variants and Platelet Reactivity for Guiding Antiplatelet Treatment
A Book

by Agency for Healthcare Research and Quality,U.s. Department of Health and Human Services

  • Publisher : CreateSpace
  • Release : 2015-02-11
  • Pages : 362
  • ISBN : 9781508439332
  • Language : En, Es, Fr & De
GET BOOK

Platelets play a role in the development of atherosclerotic vascular diseases such as acute and chronic coronary artery disease, ischemic cerebrovascular disease (i.e., ischemic stroke or transient ischemic attack), and peripheral arterial disease. Specifically, platelet activation and aggregation, and the interaction of platelets with blood cells and the endothelium, contribute to the pathophysiology of these diseases. Furthermore, platelets participate in thrombus formation in the setting of atrial fibrillation. Because of the importance of platelets in disease processes that often culminate in major adverse clinical events (e.g., myocardial infarction, ischemic stroke, or cardiovascular death), there is a strong rationale for the development of therapies specifically targeting platelet function for the primary and secondary prevention of cardiovascular disease. Because patient response to antiplatelet treatments is variable, there is also great interest in developing biomarkers to predict treatment response and guide treatment selection. Approximately 82 million Americans currently suffer from some form of cardiovascular disease. Randomized controlled trials have established dual antiplatelet treatment with clopidogrel and aspirin as the current standard of care for medical and interventional management of acute coronary syndromes. Dual antiplatelet treatment is also recommended for patients undergoing PCI with placement of stents (either bare metal or drug eluting). Randomized controlled trials support the use of clopidogrel in patients who have experienced acute cardiovascular events (e.g., stroke) and those with peripheral arterial disease. For patients with atrial fibrillation and contraindications to vitamin K antagonists, the ACTIVE A (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) trial suggested that the combination of clopidogrel and aspirin is more effective than aspirin alone for preventing thromboembolic disease. Since the approval of clopidogrel by the U.S. Food and Drug Administration (FDA) for routine clinical use, the drug has become one of the most commonly prescribed agents in the United States. However, patient response to clopidogrel-based antiplatelet therapy is variable both between patients and across multiple measurements within a patient, with some patients showing no or minimal platelet response to clopidogrel administration (often termed clopidogrel “nonresponsiveness” or “resistance”). Alternatives to standard clopidogrel treatment include higher dose clopidogrel regimens and the use of other antiplatelet agents, such as prasugrel or ticagrelor. Given the availability of alternative antiplatelet strategies and concern about adverse clinical outcomes in clopidogrel nonresponders, research has focused on methods to identify patients who are unlikely to benefit from clopidogrel-based treatment. The question of identifying the optimal antiplatelet therapy may also carry cost implications because generic clopidogrel products are now available in the United States.

EPIDURAL ANESTHESIA FOR MANAGEMENT OF PSEUDO ANEURYSM OF FEMORAL ARTERY IN ASA- IV PATIENT ON DUAL ANTIPLATELET THERAPY: CASE REPORT PARADIGM SHIFT IN ANAESTHESIA PRACTICE

EPIDURAL ANESTHESIA FOR MANAGEMENT OF PSEUDO ANEURYSM OF FEMORAL ARTERY IN ASA- IV PATIENT ON DUAL ANTIPLATELET THERAPY: CASE REPORT PARADIGM SHIFT IN ANAESTHESIA PRACTICE
A Book

by Sherif Abeer

  • Publisher : Unknown Publisher
  • Release : 2017
  • Pages : 329
  • ISBN : 9876543210XXX
  • Language : En, Es, Fr & De
GET BOOK

Epidural anesthesia for management of pseudo aneurysm of femoral artery in ASA- IV patient on dual antiplatelet therapy: Case report and a paradigm shift in anaesthesia practiceAbeer A. Sherif, MD(1), Abdulatif Araji, MD(2) (1) Professor of anaesthesia & Pain medicine, Faculty of Medicine, El-menufia university, Consultant & Chief anaesthesiologist NMC royal hospital UAE (2) Vascular surgeon, NMC Royal hospital, UAEIntroduction: Anticoagulation achieved with dual antiplatelet therapy is becoming increasingly common after coronary angioplasty and represents an everyday challenge to the anaesthesiologists when neuraxial anaesthesia is to be considered specially in high risk patients with multiple comorbidities. Epidural hematoma is a rare but potentially devastating complication of neuraxial anesthesia. To date, no clear data addressing the safety of epidural anesthesia in patients on dual antiplatelet therapy. Despite being extremely rare, the development of epidural hematoma is a known risk after epidural analgesia. The third National Audit Project of the Royal College of Anesthetists found an incidence of two in 100 000 cases. The incidence of spontaneous epidural hematoma is rarer, estimated at 1 per 1 000 000 patients per year, most going undetected. Antiplatelet agents are known to be protective in most patients at increased risk of occlusive vascular events, including those with an acute myocardial infarction, ischemic stroke, angina, peripheral arterial disease, or atrial fibrillation. Brilianta (ticagrelor) is a platelet adenosine diphosphate (ADP) P2Y12 receptor inhibitor, a new oral anticoagulants are approved for a variety of clinical syndromes like coronary artery disease, peripheral vascular disease, or ischaemic strokes. Current ASRA recommendations to stop Brilianta (Ticagrelor) therapy 5 - 7 days before the surgery are based on level III evidence such as clinical judgement and sporadic case reports of epidural hematoma after regional analgesia, in patients with a history of taking Tecagrelor in combination with other anticoagulants ( level C evidence). To date, no prospective studies have investigated the safety of epidural analgesia in patients actively taking Ticagrelor.Methods: A 80-year-old man presented with a history of swelling and redness in his left groin. Patients was on aspirin and brilianta after angioplasty 3 month ago, ischemic nephropathy, COPD, sever chest infection, heart failure and pacemaker in place. Epidural anesthesia was planned because of the poor general condition of the patient. Epidural was conducted in the sitting position using L 3- 4 interspaces, 10 ml of bupivacaine 0.5% was injected in the epidural catheter. Primary repair of the femoral vein performed, along with the patching of the left common femoral artery. The surgical procedure lasted for 6 hours and the patient was shifted to ICU for monitoring. The intraoperative as well as the postoperative period remained uneventful.Discussion:The risk of central neuraxial blockade in patients treated with newer antiplatelet drugs is unclear. However, a disturbing lack of data exists concerning the safety of neuroaxial blockade in such patients, with a wide difference in opinion not only among anesthetists but also between published guidelines. The American Society of Regional Anesthesia agreed on an interval of 5 - 7 days between discontinuation of Brilianta (Ticagrelor) therapy and neuraxial blockade. In the current case the patient had recently undergone a coronary artery stent implantation and was treated with both Brilianta, and aspirin. Despite this dual antiplatelet therapy, uneventful epidural anesthesia at two levels was carried out. Our case report demonstrate that, for certain high-risk patients, the benefit of placing an epidural catheter while actively taking antiplatelet therapy may be considered. Conclusion:Epidural anesthesia was conducted safely for emergency vascular surgery, in high risk patient with multiple comorbidities. Decision to perform regional anesthesia in the patients receiving antithrombotic drugs should be made on an individual basis weighing risk of epidural hematoma with the benefits of regional anesthesia. This report is not meant to recommend the liberal placement of epidural catheters in patients actively taking dual antiplatelet therapy. prospective studies with a large number of patients are needed in order to give more accurate recommendation regarding performing epidural block in such population.References: 1-tHorlocker TT, Wedel DJ, Benzon H, et al. Regional anesthesia in the anticoagulated patient: defining the risks (the second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation). Reg Anesth Pain Med 2003; 28: 172u201397.2-tCook T, Counsell D, Wildsmith J. Major complications of central neuraxial block: report on the Third National Audit Project of the Royal College of Anaesthetists. Br J Anaesth 2009; 102: 179u201390.3-tHorlocker TT, Wedel DJ, Benzon H, et al. Regional anesthesia in the anticoagulated patient: defining the risks (the second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation). Regional Anesthesia and Pain Medicine 2003; 28: 172u201397.

Clopidogrel and the Newer P2Y12 Antiplatelet Agents

Clopidogrel and the Newer P2Y12 Antiplatelet Agents
Pharmacology, Clinical Uses, and Adverse Effects

by Michael P. Savage,David L. Fischman, M.d.

  • Publisher : Unknown Publisher
  • Release : 2019-02-22
  • Pages : 308
  • ISBN : 9781536149722
  • Language : En, Es, Fr & De
GET BOOK

Cardiovascular disease remains the leading cause of death in the developed world. By preventing thromboembolic events such as heart attacks and strokes, antiplatelet drugs have become a cornerstone in the treatment of cardiovascular disease. Clopidogrel is a member of the thienopyridine family which inhibit ADP-induced platelet activation by irreversibly binding to the P2Y12 receptor. Clopidogrel is one of the most commonly used medications with over 9 million prescriptions written annually. It is utilized in the treatment of a wide variety of cardiovascular disorders including acute coronary syndromes (ACS), percutaneous coronary intervention (PCI) with stents, cerebrovascular disease, peripheral vascular disease, and structural heart interventions. Most often, clopidogrel is used in combination with low dose aspirin, providing dual antiplatelet therapy (DAPT). Newer, more potent P2Y12 inhibitors, prasugrel and ticagrelor, are now available as alternatives to clopidogrel. These newer agents have been shown to be more effective than clopidogrel in reducing ischemic events in patients with ACS. Recently a novel intravenous P2Y12 inhibitor, cangrelor, has become available for use during PCI in patients who have not been pretreated with an oral P2Y12 inhibitor. This book examines virtually all aspects of P2Y12 inhibitors pharmacology, clinical uses, randomized trial results, guideline recommendations, and adverse drug effects. Important fundamental issues are reviewed including comparative pharmacology of P2Y12 inhibitors, randomized trials of clopidogrel in patients with coronary artery disease, DAPT duration after PCI, and role of platelet function testing. The newer P2Y12 inhibitors (prasugrel, ticagrelor, and cangrelor) receive special focus. Use of antiplatelet therapy in specific patient populations is discussed including patients with coronary bypass graft surgery, peripheral vascular disease, cerebrovascular disease, and structural heart disease. Management of antiplatelet therapy in patients who require anticoagulation is a particularly challenging clinical setting and is the topic of a featured review. Finally, adverse drug effects and reactions are examined in a section highlighting clopidogrel resistance, clopidogrel hypersensitivity, and bleeding complications. This book is designed to provide a comprehensive review of clopidogrel and the newer P2Y12 inhibitors. Towards that end, the authors have enlisted an internationally renowned group of experts as contributors. It is intended to be a resource for clinicians, scientists, pharmacologists, and all healthcare professionals involved in the management of cardiovascular disease.

New Technologies for the Treatment of Coronary and Structural Heart Diseases

New Technologies for the Treatment of Coronary and Structural Heart Diseases
A Book

by Alberto Polimeni

  • Publisher : MDPI
  • Release : 2020-12-03
  • Pages : 352
  • ISBN : 3039435590
  • Language : En, Es, Fr & De
GET BOOK

There has been significant progress in the field of interventional cardiology, from the development of newer devices to newer applications of technology, resulting in improved cardiovascular outcomes. The goal of this Special Issue is to update practicing clinicians and provide a comprehensive collection of original articles, reviews, and editorials. To this end, we invited state-of-the-art reviews, including reviews of new technology and therapeutics, as well as original research in this area to be considered for inclusion in this issue. Examples include the history and evolution of interventional techniques, reviews of specific devices and technologies for coronary artery disease (i.e., stent technology, atherectomy devices, coronary physiology, intracoronary imaging, and robotics), structural heart diseases (i.e., ASD: atrial septal defect; LAAC: left atrial appendage closure; MC: MitraClip; PFO: patent foramen ovale; TAVI: transcatheter aortic valve implantation), advances in the management of challenging coronary anatomy, new biomarkers of cardiovascular disease (noncoding RNAs, etc.), and interventional techniques in the management of heart failure, peripheral arterial diseases, and pulmonary embolism. This Special Issue presents the most recent advances in the field of coronary and structural heart diseases as well as their implications for future patient care.

Vascular Medicine

Vascular Medicine
A Companion to Braunwald's Heart Disease

by Mark A. Creager,Joshua A. Beckman,Joseph Loscalzo

  • Publisher : Elsevier Health Sciences
  • Release : 2012
  • Pages : 854
  • ISBN : 1437729304
  • Language : En, Es, Fr & De
GET BOOK

Companion v. to: Braunwald's heart disease.

Vascular Medicine E-Book

Vascular Medicine E-Book
A Companion to Braunwald's Heart Disease

by Mark Creager,Joseph Loscalzo,Joshua A. Beckman

  • Publisher : Elsevier Health Sciences
  • Release : 2012-08-30
  • Pages : 880
  • ISBN : 1455737364
  • Language : En, Es, Fr & De
GET BOOK

Make the most of today's innovative medical therapies, advances in vascular imaging, and new drugs to improve your patients' cardiovascular health with Vascular Medicine, 2nd Edition. This comprehensive, clinically-focused volume in the Braunwald's Heart Disease family provides an in-depth, state-of-the-art review of all vascular diseases, with an emphasis on pathophysiology, diagnosis, and management - giving you the evidence-based guidance you need to make appropriate therapeutic decisions on behalf of your patients. Consult this title on your favorite e-reader with intuitive search tools and adjustable font sizes. Elsevier eBooks provide instant portable access to your entire library, no matter what device you’re using or where you’re located. Gain a state-of-the-art understanding of the pathophysiology, diagnosis, and management of arterial disease, venous disease, lymph dysfunction, connective tissue disease, vascular disease, and vascular manifestations of systemic disease. Benefit from the knowledge and experience of Dr. Mark A. Creager (editor of the Vascular Medicine society journal), Dr. Joshua A. Beckman, and Dr. Joseph Loscalzo, and benefit from their practice rationales for all of today’s clinical therapies. Easily reference Braunwald’s Heart Disease, 9th Edition for further information on topics of interest. Get up-to-date information on new combination drug therapies and management of chronic complications of hypertension. Learn the best methods for aggressive patient management and disease prevention to ensure minimal risk of further cardiovascular problems. Stay current with ACC/AHA and ECC guidelines and the best ways to implement them in clinical practice. Enhance your visual perspective with an all-new, full-color design throughout. Utilize behavior management as an integral part of treatment for your hypertensive and pre-hypertensive patients. Effectively manage special populations with chronic hypertensive disease, as well as hypertension and concomitant disease. Access the complete contents online and download images at www.expertconsult.com.

Platelets

Platelets
A Book

by Alan D. Michelson,Marco Cattaneo,Andrew Frelinger,Peter Newman

  • Publisher : Academic Press
  • Release : 2019-03-07
  • Pages : 1268
  • ISBN : 0128134690
  • Language : En, Es, Fr & De
GET BOOK

Platelets, Fourth Edition, integrates the entire field of platelet biology, pathophysiology, and clinical medicine with contributions from 142 world experts from 18 countries. This award-winning reference provides clear presentations by basic scientists on the cellular, molecular, and genetic mechanisms of platelets and the role of platelets in thrombosis, hemorrhage, inflammation, antimicrobial host defense, wound healing, angiogenesis and cancer. It also provides start-of-the-art presentations by hematologists, cardiologists, stroke physicians, blood bankers, pathologists and other clinicians on platelet function testing, disorders of platelet numbers and function, antiplatelet therapy and therapy to increase platelet numbers and/or function. Since the publication of the Third Edition of Platelets, there has been a rapid expansion of knowledge in both basic biology of platelets and the clinical approach to platelet-related diseases. This Fourth Edition of Platelets draws all this information into a single, comprehensive and authoritative resource. Comprehensive and definitive source of state-of-the-art knowledge about platelets Integrates the entire field of platelet biology, pathophysiology, and clinical medicine Written for clinicians, pathologists and scientists by 142 world-renowned experts from 18 countries Completely revised and updated, with 11 new chapters on topics such as platelet glycobiology, the platelet transcriptome, platelet inhibitory receptors, platelet function testing in clinical research trials, therapeutic platelet-rich plasma in wound healing, and new antiplatelet drugs Full color textbook with over 250 illustrations and 15,000 references

Coagulopathy, An Issue of Oral and Maxillofacial Surgery Clinics of North America,

Coagulopathy, An Issue of Oral and Maxillofacial Surgery Clinics of North America,
A Book

by Jeffrey D. Bennett,Elie M. Ferneini

  • Publisher : Elsevier Health Sciences
  • Release : 2016-10-18
  • Pages : 329
  • ISBN : 0323477100
  • Language : En, Es, Fr & De
GET BOOK

This issue of Oral and Maxillofacial Surgery Clinics of North America focuses on Coagulopathy, and is edited by Drs. Jeffrey Bennett and Elie Ferneini. Articles will include: Perioperative Patient Evaluation: What the Oral Surgeon Needs to Know; Hypercoagulable States: What the Oral Surgeon Needs to Know; ASA, Plavix, and Other Antiplatelet Medications: What the Oral Surgeon Needs to Know; Heparin and Lovenox: What the Oral Surgeon Needs to Know; Blood Products: What the Oral Surgeon Needs to Know; Interventional Radiology and Bleeding Disorders: What the Oral Surgeon Needs to Know; Platelet Disorders: What the Oral Surgeon Needs to Know; Systemic Disease and Bleeding disorders: What the Oral Surgeon Needs to Know; Hemophilia: What the Oral Surgeon Needs to Know; Damage Control Resuscitation: What the Oral Surgeon Needs to Know; Hemostasis Agents: What the Oral Surgeon Needs to Know; Coumadin and Newer Agents: What the Oral Surgeon Needs to Know; and more!

Textbook of Interventional Cardiology E-Book

Textbook of Interventional Cardiology E-Book
A Book

by Eric J. Topol,Paul S. Teirstein

  • Publisher : Elsevier Health Sciences
  • Release : 2019-07-25
  • Pages : 1168
  • ISBN : 0323568122
  • Language : En, Es, Fr & De
GET BOOK

From new research and equipment to new procedures, applications, and approaches, the field of interventional cardiology is one of the fastest-changing areas in medicine. Increasing data and recent technological advances have resulted in exciting changes – and an even greater need for cutting-edge, authoritative guidance on current practice. Textbook of Interventional Cardiology, 8th Edition, covers the theories, trends, and applications of diagnostic and interventional cardiology that cardiologists, cardiac surgeons, vascular surgeons, referring physicians, and advanced practitioners need to know. Focuses on the latest treatment protocols for managing patients at every level of complexity. Includes all-new chapters on Coronary Stenting, Diagnosis and Treatment of Coronary Microvascular Disease, Percutaneous Transcatheter Valve in Valve Implantation, and Percutaneous Tricuspid Valve Repair. Features hundreds of new illustrations, tables, and boxes for visual clarity and quick reference. Offers expanded coverage of transcatheter aortic valve interventions with extensive updates on practice implications. Discusses hot topics such new atherectomy devices, percutaneous mitral valve replacement, and percutaneous treatment of paravalvular leak. Provides the unique insights of expert leaders in the field who have pioneered today’s innovative devices and techniques and lend their own analysis of practical, evidence-based clinical applications. Presents the most recent data on how genomics and genetics impact interventional cardiology. Provides an in-depth understanding of cardiology, making it well suited for cardiology and interventional cardiology exam preparation.

CSI Cardiology Update 2018

CSI Cardiology Update 2018
A Book

by Kewal C Goswami

  • Publisher : Jaypee Brothers Medical Publishers
  • Release : 2019-02-28
  • Pages : 1158
  • ISBN : 9352705211
  • Language : En, Es, Fr & De
GET BOOK

Interventional Cardiology in the Elderly

Interventional Cardiology in the Elderly
A Book

by Harald Rittger

  • Publisher : Springer
  • Release : 2015-10-13
  • Pages : 162
  • ISBN : 3319211420
  • Language : En, Es, Fr & De
GET BOOK

This book provides an in depth review of the current practice in treating elderly patients with coronary artery disease (CAD) as well as an update of the existing literature. It is intended to reflect the current science of elderly patients with stable angina, acute coronary syndromes and those patients who are forwarded for CAGB procedures. Evidence in the elderly patient group is often limited and/or non-existent therefore the main challenge, even for further research, will be to define the role of geriatric preconditions and its impact on outcome. A second topic will be to clarify how, if ever, existing cardiological outcome values like mortality can be applied to elderly patients or if other values like improvement of functional status or quality of life are more suitable parameters to measure interventional success in elderly patients. The role of pharmacotherapy in advanced age has to be discussed. These topics will be embedded in epidemiological, pathophysiological and ethical aspects of interventional treatment of CAD in older age.

Peripheral Artery Disease: New Insights for the Healthcare Professional: 2011 Edition

Peripheral Artery Disease: New Insights for the Healthcare Professional: 2011 Edition
ScholarlyPaper

by Anonim

  • Publisher : ScholarlyEditions
  • Release : 2012-01-09
  • Pages : 24
  • ISBN : 1464912297
  • Language : En, Es, Fr & De
GET BOOK

Peripheral Artery Disease: New Insights for the Healthcare Professional: 2011 Edition is a ScholarlyPaper™ that delivers timely, authoritative, and intensively focused information about Peripheral Artery Disease in a compact format. The editors have built Peripheral Artery Disease: New Insights for the Healthcare Professional: 2011 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Peripheral Artery Disease in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Peripheral Artery Disease: New Insights for the Healthcare Professional: 2011 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.

Vascular Medicine: A Companion to Braunwald's Heart Disease E-Book

Vascular Medicine: A Companion to Braunwald's Heart Disease E-Book
A Book

by Mark Creager,Joseph Loscalzo,Joshua A. Beckman

  • Publisher : Elsevier Health Sciences
  • Release : 2019-05-22
  • Pages : 880
  • ISBN : 0323636012
  • Language : En, Es, Fr & De
GET BOOK

With authoritative coverage of everything from recent discoveries in the field of vascular biology to recent clinical trials and evidence-based treatment strategies, Vascular Medicine, 3rd Edition, is your go-to resource for improving your patients’ cardiovascular health. Part of the Braunwald family of renowned cardiology references, this updated volume integrates a contemporary understanding of vascular biology with a thorough review of clinical vascular diseases, making it an ideal reference for vascular medicine specialists, general cardiologists, interventional cardiologists, vascular surgeons, and interventional radiologists. Incorporates technologic advances in vascular imaging – including ultrasound, MRI, CTA, and catheter-based angiography – along with more than 230 new figures, providing an up-to-date and complete view of the vascular system and vascular diseases. Covers novel antithrombotic therapies for peripheral artery disease and venous thromboemboism, advances in endovascular interventions for aortic aneurysms, and today’s best surgical treatments for vascular diseases. Includes seven new chapters: Pathobiology of Aortic Aneurysms; Pathobiology and Assessment of Cardiovascular Fibrosis; Large Vessel Vasculitis; Medium and Small Vessel Vasculitis; Epidemiology and Prognosis of Venous Thromboembolic Disease; Fibromuscular Dysplasia; and Dermatologic Manifestations of Vascular Disease. Discusses methods for aggressive patient management and disease prevention to ensure minimal risk of further cardiovascular problems. Keeps you current with ACC/AHA and ECC guidelines and the best ways to implement them in clinical practice.

Antiplatelet Therapy In Ischemic Heart Disease

Antiplatelet Therapy In Ischemic Heart Disease
A Book

by Stephen D. Wiviott

  • Publisher : John Wiley & Sons
  • Release : 2009-01-26
  • Pages : 312
  • ISBN : 1444303341
  • Language : En, Es, Fr & De
GET BOOK

* Draws from expertise of leaders in antiplatelet therapy * Easy-to-use layout enables rapid browsing * Edited by a member of the prestigious TIMI study group withlong-standing experience in the field

Carotid Artery Stenting: The Basics

Carotid Artery Stenting: The Basics
A Book

by Jacqueline Saw

  • Publisher : Springer Science & Business Media
  • Release : 2009-06-26
  • Pages : 264
  • ISBN : 9781603273145
  • Language : En, Es, Fr & De
GET BOOK

Over the past three decades, carotid artery stenting has evolved to become a promising and viable alternative to carotid endarterectomy, especially for patients deemed to have high surgical risks. In Carotid Artery Stenting: The Basics, Jacqueline Saw and a panel of international experts on carotid artery stenting discuss in depth the details of all contemporary aspects of carotid stenting, while reviewing supporting studies, guidelines, technical perspectives, and peri-procedural management. This textbook serves as a learning resource on the multifaceted management of patients with carotid artery stenosis, with the key focus on extracranial carotid artery stenting. Additional sections detail the specifics of setting up and maintaining a laboratory and discuss the preparation of the carotid artery stenting procedure from both the patient and operator’s perspective. Authoritative and highly practical, Carotid Artery Stenting: The Basics is an accessible guide and valuable resource for today’s cardiologists, radiologists, and vascular surgeons.

Ferri's Clinical Advisor 2013

Ferri's Clinical Advisor 2013
5 Books in 1

by Fred F. Ferri

  • Publisher : Elsevier Health Sciences
  • Release : 2012-06-01
  • Pages : 1600
  • ISBN : 032308432X
  • Language : En, Es, Fr & De
GET BOOK

With the 2013 edition of Ferri’s Clinical Advisor, you can access current diagnostic and therapeutic information on more than 700 common medical conditions faster and more effectively than ever before. Dr. Ferri’s popular "5 books in 1" format provides quick guidance on vitamin-D deficiency, statin-induced muscle syndrome, postural tachycardia syndrome (POTS), and much more. Rapidly find the answers you need with separate sections on diseases and disorders, differential diagnosis, clinical algorithms, laboratory results, and clinical preventive services, plus an at-a-glance format that uses cross-references, outlines, bullets, tables, boxes, and algorithms to expedite reference. Review normal values and interpret results for more than 200 lab tests. Get the insurance billing codes you require, including ICD-9-CM codes, to expedite insurance reimbursements. Improve your practice’s efficiency with cost-effective referral and consultation guidelines. Identify and treat a broader range of disorders with 25 new topics in the Diseases & Disorders section, including vitamin-D deficiency, oral cancer, hypovitaminosis, sarcoma, hyperemesis in pregnancy, androgen deficiency in the elderly male, statin-induced muscle syndrome, and more. Improve your interpretation of presenting symptoms with 41 new topics and 7 new references in the Differential Diagnosis section.

Antithrombotic Drug Therapy in Cardiovascular Disease

Antithrombotic Drug Therapy in Cardiovascular Disease
A Book

by Arman T. Askari,A. Michael Lincoff

  • Publisher : Springer Science & Business Media
  • Release : 2010-03-20
  • Pages : 475
  • ISBN : 9781603272353
  • Language : En, Es, Fr & De
GET BOOK

Substantial morbidity and mortality remains associated with thrombotic events has stimulated the rapid expansion of the available armamentarium to combat pathologic thrombosis. Pathologic thrombosis plays an essential role in the pathogenesis of acute coronary syndromes (ACS), ischemic complications of percutaneous coronary intervention (PCI), venous thromboembolic disease, and embolic complications of arrhythmias and various cardiomyopathies. Written by experts in the field, Antithrombotic Drug Therapy in Cardiovascular Disease carefully examines individual and various combinations of the available antithrombotic regimens including fibrinolytic agents, antiplatelet therapies (aspirin, thieneopyridines, glycoprotein IIb/IIIa inhibitors), and anticoagulant therapies (unfractionated heparin, low-molecular-weight heparins, direct thrombin inhibitors, and synthetic factor X inhibitors), non-ST-segment elevation (NSTE) ACS and ST-segment elevation myocardial infarction (STEMI). A detailed overview, Antithrombotic Drug Therapy in Cardiovascular Disease presents the evidence demonstrating the efficacy of available antithrombotic therapies in specific disease states such as atrial fibrillation, cardiomyopathy, valvular heart disease, and heparin-induced thrombocytopenia (HIT).

Goldman-Cecil Medicine E-Book

Goldman-Cecil Medicine E-Book
A Book

by Lee Goldman,Andrew I. Schafer

  • Publisher : Elsevier Health Sciences
  • Release : 2019-08-16
  • Pages : 2972
  • ISBN : 0323550878
  • Language : En, Es, Fr & De
GET BOOK

To be the best doctor you can be, you need the best information. For more than 90 years, what is now called Goldman-Cecil Medicine has been the authoritative source for internal medicine and the care of adult patients. Every chapter is written by acclaimed experts who, with the oversight of our editors, provide definitive, unbiased advice on the diagnosis and treatment of thousands of common and uncommon conditions, always guided by an understanding of the epidemiology and pathobiology, as well as the latest medical literature. But Goldman-Cecil Medicine is not just a textbook. Throughout the lifetime of each edition, periodic updates continually include the newest information from a wide range of journals. Furthermore, Goldman-Cecil Medicine is available for all users of ClinicalKey, Elsevier’s full library of subspecialty textbooks that can be accessed by readers who may want even more in-depth information. More than 400 chapters authored by a veritable "Who’s Who" of modern medicine A practical, templated organization with an emphasis on evidence-based references Thousands of algorithms, figures, and tables that make its information readily accessible Supplemented by over 1500 board-style questions and answers to help you prepare for certification and recertification examinations

Management of Bleeding Patients

Management of Bleeding Patients
A Book

by Jun Teruya

  • Publisher : Springer Nature
  • Release : 2021
  • Pages : 329
  • ISBN : 3030563383
  • Language : En, Es, Fr & De
GET BOOK